Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients.

@article{Lorigan2006PhaseIT,
  title={Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients.},
  author={Paul C. Lorigan and Pippa Corrie and David J. Chao and Paul Nathan and Tanya Ahmad and Richard Marais and Karen Burk and Fredrik Erlandsson and MartinE. Gore and Tim Eisen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={8012}
}
8012 Background: Sorafenib inhibits tumor cell proliferation and angiogenesis through blockade of multiple kinases including Raf, VEGFR-2/-3, and PDGFR-β. In Phase I/II trials, sorafenib was generally well tolerated as a monotherapy or in combination with other agents. A Phase I study in combination with dacarbazine (DTIC) showed encouraging activity, which warranted this Phase II study. METHODS This multi-center, open-label, two-stage (30 patients in Stage 1; 52 in Stage 2), uncontrolled… CONTINUE READING

Similar Papers

Loading similar papers…